Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma

被引：18
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka 5898511, Japan
来源：
LIVER CANCER | 2018年 / 7卷 / 02期
关键词：
PHASE-3; TRIAL; DOUBLE-BLIND; SYSTEMIC THERAPY; SORAFENIB; REGORAFENIB; MULTICENTER; PLACEBO; ANGIOGENESIS; GROWTH; SAFETY;
D O I：
10.1159/000488542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：123 / 133
页数：11
相关论文
共 50 条
  • [1] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [2] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [3] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    [J]. LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [4] Advanced Renal Cell Carcinoma Cabozantinib Monotherapy is the Second-line Therapy Standard
    Schmale, Ine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 638 - 639
  • [5] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Personeni, Nicola
    Pressiani, Tiziana
    Bozzarelli, Silvia
    Rimassa, Lorenza
    [J]. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (10) : 788 - 803
  • [6] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Nicola Personeni
    Tiziana Pressiani
    Silvia Bozzarelli
    Lorenza Rimassa
    [J]. World Journal of Gastrointestinal Oncology, 2019, (10) : 788 - 803
  • [7] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen L.
    Lim, Ho Yeong
    Baron, Ari D.
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas
    Lougheed, Julie C.
    Milwee, Steven
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    [J]. ESMO OPEN, 2020, 5 (04) : 1 - 9
  • [8] Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
    Maximilian Sieg
    Michael Hartmann
    Utz Settmacher
    Habibollah Arefian
    [J]. BMC Gastroenterology, 20
  • [9] Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
    Sieg, Maximilian
    Hartmann, Michael
    Settmacher, Utz
    Arefian, Habibollah
    [J]. BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [10] Advanced HCC Cabozantinib, new Addition to Second-line Therapy
    Bischoff, Angelika
    [J]. VISCERAL MEDICINE, 2019, 35 (02) : 138 - 138
12345